{
  "component_scores": {
    "joint_involvement": {
      "score": 5,
      "justification": "Patient facts mention polyarthrite rhumatoïde and multiple joint involvement, including large joints (shoulders, elbows, hips, knees) as well as small joints (MCPs, PIPs). This fits the criteria for a score of 5 points."
    },
    "serology": {
      "score": 0,
      "justification": "There are no lab results mentioned in the patient facts. Thus, there is no serologic evidence available to score serology category B."
    },
    "acute_phase": {
      "score": 0,
      "justification": "No laboratory values for CRP or ESR were provided in the patient facts, therefore this component receives a score of 0 points."
    },
    "duration": {
      "score": 1,
      "justification": "DMARD treatment is mentioned (methotrexate), which suggests that the disease has been ongoing long enough to be treated with DMARDs. This contributes a duration score of 1 point."
    }
  },
  "acr_eular_total": 6,
  "treatment_context": {
    "has_dmard": true,
    "treatment_strength": "strong",
    "justification": "The patient is receiving methotrexate, which falls under the category of DMARDs. Methotrexate is a first-line csDMARD and its presence strongly supports the diagnosis of RA+ (established Rheumatoid Arthritis)."
  },
  "final_label": "RA+",
  "classification_rationale": "The patient meets the ACR-EULAR criteria for classification as RA+. The joint involvement score of 5 is supported by multiple large and small joints being mentioned. Methotrexate treatment, a first-line DMARD, indicates that the disease has been established long enough to be treated with this medication. Since there are no serologic results available (serology category B), we rely on the clinical context (DMARDs) for diagnosis.",
  "confidence": "high",
  "patient_id": "0018",
  "agent": "Agent2_LLM_Reasoning_BALANCED",
  "retrieved_guidelines": [
    {
      "title": "Clinical Context",
      "content": "Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "text": "Clinical Context Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "relevance_score": 4.683000883810066
    },
    {
      "title": "Category A: Joint Involvement (0-5 points)",
      "content": "- 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "text": "Category A: Joint Involvement (0-5 points) - 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "relevance_score": 2.188326647736484
    },
    {
      "title": "Classification Criteria (Score-based algorithm)",
      "content": "A score of ≥6/10 is needed for classification as definite RA.",
      "text": "Classification Criteria (Score-based algorithm) A score of ≥6/10 is needed for classification as definite RA.",
      "relevance_score": 0.7797536738596373
    }
  ],
  "guideline_citation": "Aletaha D, et al. Arthritis Rheum. 2010;62(9):2569-2581",
  "evidence_trace": [
    {
      "type": "disease_mention",
      "stay_id": "S0035",
      "line_no": 1,
      "snippet": "Antécédents : traitement par méthotrexate pour PR depuis 2021."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0035",
      "line_no": 5,
      "snippet": "Diagnostic : polyarthrite rhumatoïde confirmée."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0035",
      "line_no": 5,
      "snippet": "Diagnostic : polyarthrite rhumatoïde confirmée."
    },
    {
      "type": "drug",
      "name": "methotrexate",
      "stay_id": "S0035",
      "line_no": 1,
      "snippet": "Antécédents : traitement par méthotrexate pour PR depuis 2021."
    }
  ]
}